Literature DB >> 24469548

High level expression, purification and immunogenicity analysis of a protective recombinant protein against botulinum neurotoxin type E.

Ebrahim Valipour1, Mir-Latif Moosavi, Jafar Amani, Shahram Nazarian.   

Abstract

Botulinum neurotoxin type E heavy chain consists of two domains: N-terminal half as a translocation domain and C-terminal half (Hcc) as a binding domain. In this research a synthetic gene fragment encoding the binding domain of botulinum neurotoxin type E (BoNT/E-Hcc) was highly expressed in Escherichia coli by pGEX4T-1 vector. After purification, the recombinant BoNT/E-Hcc was evaluated by SDS-PAGE and western blot (immunoblot) analysis. Average yields obtained in this research were 3.7 mg recombinant BoNT/E-Hcc per liter of bacterial culture. The recombinant protein was injected in mice for study of its protection ability against botulinum neurotoxin type E challenges. The challenge studies showed that, vaccinated mice were fully protected against 10⁴ × minimum lethal dose of botulinum neurotoxin type E.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24469548     DOI: 10.1007/s11274-014-1609-0

Source DB:  PubMed          Journal:  World J Microbiol Biotechnol        ISSN: 0959-3993            Impact factor:   3.312


  26 in total

1.  Cloning, high level expression, purification, and crystallization of the full length Clostridium botulinum neurotoxin type E light chain.

Authors:  Rakhi Agarwal; Subramaniam Eswaramoorthy; Desigan Kumaran; John J Dunn; Subramanyam Swaminathan
Journal:  Protein Expr Purif       Date:  2004-03       Impact factor: 1.650

2.  Cloning, high-level expression, single-step purification, and binding activity of His6-tagged recombinant type B botulinum neurotoxin heavy chain transmembrane and binding domain.

Authors:  Yu Zhou; Bal Ram Singh
Journal:  Protein Expr Purif       Date:  2004-03       Impact factor: 1.650

3.  Characterization of the monoclonal antibody response to botulinum neurotoxin type A in the complexed and uncomplexed forms.

Authors:  Haiyang Zhao; Keiji Nakamura; Tomoko Kohda; Masafumi Mukamoto; Shunji Kozaki
Journal:  Jpn J Infect Dis       Date:  2012       Impact factor: 1.362

4.  Trivalent vaccine against botulinum toxin serotypes A, B, and E that can be administered by the mucosal route.

Authors:  Easwaran Ravichandran; Fetweh H Al-Saleem; Denise M Ancharski; Mohammad D Elias; Ajay K Singh; Mohammad Shamim; Yujing Gong; Lance L Simpson
Journal:  Infect Immun       Date:  2007-03-19       Impact factor: 3.441

5.  Subunit vaccine against the seven serotypes of botulism.

Authors:  Michael R Baldwin; William H Tepp; Amanda Przedpelski; Christina L Pier; Marite Bradshaw; Eric A Johnson; Joseph T Barbieri
Journal:  Infect Immun       Date:  2007-12-10       Impact factor: 3.441

6.  Cloning, high level expression and immunogenicity of 1163-1256 residues of C-terminal heavy chain of C. botulinum neurotoxin type E.

Authors:  Abdoulreza Agheli Mansour; Seyed Latif Mousavi; Iraj Rasooli; Shahram Nazarian; Jafar Amani; Nima Farhadi
Journal:  Biologicals       Date:  2009-10-29       Impact factor: 1.856

7.  Codon usages in different gene classes of the Escherichia coli genome.

Authors:  S Karlin; J Mrázek; A M Campbell
Journal:  Mol Microbiol       Date:  1998-09       Impact factor: 3.501

8.  Expression of tetanus toxin fragment C in E. coli: high level expression by removing rare codons.

Authors:  A J Makoff; M D Oxer; M A Romanos; N F Fairweather; S Ballantine
Journal:  Nucleic Acids Res       Date:  1989-12-25       Impact factor: 16.971

9.  Functional characterisation of tetanus and botulinum neurotoxins binding domains.

Authors:  G Lalli; J Herreros; S L Osborne; C Montecucco; O Rossetto; G Schiavo
Journal:  J Cell Sci       Date:  1999-08       Impact factor: 5.285

Review 10.  Botulinum neurotoxins and botulism: a novel therapeutic approach.

Authors:  Jeeraphong Thanongsaksrikul; Wanpen Chaicumpa
Journal:  Toxins (Basel)       Date:  2011-05-13       Impact factor: 4.546

View more
  6 in total

1.  High-level expression and characterization of bioactive human truncated variant of hepatocyte growth factor in Escherichia coli.

Authors:  Xiaohua Wang; Haifeng Liu; Zhongmin Zhang; Yang Liu; Yuting Li; Jinqiu Gui; Yanhui Chu
Journal:  World J Microbiol Biotechnol       Date:  2014-08-14       Impact factor: 3.312

2.  Novel integration strategy coupling codon and fermentation optimization for efficiently enhancing sarcosine oxidase (SOX) production in recombinant Escherichia coli.

Authors:  Yanjun Tong; Hailin Yang; Yu Xin; Ling Zhang; Wu Wang
Journal:  World J Microbiol Biotechnol       Date:  2015-03-26       Impact factor: 3.312

3.  Immunogenicity evaluation of rBoNT/E nanovaccine after mucosal administration.

Authors:  Mohamad Javad Bagheripour; Firouz Ebrahimi; Abbas Hajizade; Shahram Nazarian
Journal:  Iran J Basic Med Sci       Date:  2019-04       Impact factor: 2.699

4.  A Novel Strategy for the Preparation of Codon-Optimized Truncated Ulp1 and its Simplified Application to Cleavage the SUMO Fusion Protein.

Authors:  Xiaohua Wang; Haifeng Liu; Yawei Liu; Yuting Li; Lei Yan; Xiaohuan Yuan; Yufei Zhang; Yan Wu; Jieting Liu; Chunlei Zhang; Yanhui Chu
Journal:  Protein J       Date:  2016-04       Impact factor: 2.371

5.  Functional EL-HN Fragment as a Potent Candidate Vaccine for the Prevention of Botulinum Neurotoxin Serotype E.

Authors:  Zhen Li; Jiansheng Lu; Xiao Tan; Rong Wang; Qing Xu; Yunzhou Yu; Zhixin Yang
Journal:  Toxins (Basel)       Date:  2022-02-11       Impact factor: 4.546

6.  Characterization of immune response induced against catalytic domain of botulinum neurotoxin type E.

Authors:  Priyanka Sonkar; Vinita Chauhan; Ritika Chauhan; Nandita Saxena; Ram Kumar Dhaked
Journal:  Sci Rep       Date:  2020-08-18       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.